Bei Jing Shang Bao·2025-09-24 16:37Core Viewpoint - Xianweida Biotechnology Co., Ltd. is targeting the rapidly growing weight management sector and has officially submitted its IPO application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC as joint sponsors [1] Company Overview - Xianweida has completed approximately 2.2 billion yuan in financing, with investors including Tencent and Meituan [1] - The company is currently in a "burning cash" R&D phase, with no products commercialized yet, projecting zero revenue for 2023 and 2024, and expecting to generate 91 million yuan in revenue in the first half of 2025 [1][6] - Cumulative net losses have exceeded 1.2 billion yuan [1] Product Pipeline - The product pipeline focuses on GLP-1 receptor agonists, with the core product being the injectable Enoglutide (XW003), which is in the critical pre-market stage [2] - Enoglutide is a novel long-acting GLP-1 receptor agonist that enhances efficacy in glucose reduction and weight loss without triggering excessive receptor internalization [2] - The company has submitted applications for Enoglutide for overweight/obesity and type II diabetes indications in China, with expectations for commercialization by 2026 [2] Competitive Landscape - The global weight management drug market is projected to grow from $112.8 billion in 2024 to $165.9 billion by 2029, attracting significant investment [5] - Xianweida faces competition from established multinational pharmaceutical companies and local firms, with three GLP-1 drugs already approved for overweight/obesity indications and several others in late-stage clinical trials [5][6] Financial Situation - The company has incurred substantial R&D expenses, totaling over 800 million yuan from 2023 to the first half of 2025, while generating minimal revenue [6] - The net proceeds from the IPO are intended for the R&D and commercialization of Enoglutide, advancing other product pipelines, upgrading production capabilities, and working capital [6]